Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
26S proteasome non-ATPase regulatory subunit 12 (PSMD12) is a non-ATPase component of the 19S regulator (lid subcomplex) of the 26S proteasome, a large multisubunit protease complex essential for ATP-dependent degradation of ubiquitinated proteins in eukaryotic cells. PSMD12 is required for proper assembly and function of the proteasome, facilitating recognition, deubiquitination, and delivery of target proteins into the 20S catalytic core for proteolysis. It plays a vital role in protein homeostasis, cell cycle, apoptosis, and the generation of antigenic peptides for immune surveillance. Disruption of PSMD12 function (e.g., by haploinsufficient mutations) is linked to intellectual disability, autism spectrum disorder, and related neurodevelopmental syndromes. There are currently no drugs that selectively target PSMD12; most proteasome inhibitors act on the core particle rather than regulatory subunits.
(not directly targeted by current drugs; most proteasome inhibitors act on the catalytic 20S core, not on PSMD12 or other non-ATPase regulatory subunits)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 26S proteasome non-ATPase regulatory subunit 12 (PSMD12).